Table 2. 90Y-ibritumomab tiuxetan treatment in diffuse large B cell lymphoma.

Trial design	Disease	No of patients	Response rate	Response duration
After 6 cycles of CHOP [30]	Chemonaïve DLBCL	20	ORR 100% CR 95% PR 5%	2-year PFS 75% 2-year OS 95%
After 6 cycles of R-CHOP [31]	Chemonaïve, elderly DLBCL	63	ORR 88% CR/CRu 86% PR 2%	3.5-year PFS 75% 3.5-year OS 84%
After 4 cycles of R-CHOP [32]	Chemonaïve, elderly DLBCL	55	ORR 80% CR 73% PR 7%	2-year PFS 85% 2-year OS 86%
After either 4 or 6 cycles of R-CHOP [34]	Chemonaïve, early stage DLBCL	53	ORR 98% CR/CRu 79% PR 19%	5-year PFS 78% 5-year OS 94%
Monotherapy [37]	R/R DLBCL	104	ORR 44%	mPFS 1.6 - 5.9 months mOS 4.6 – 22.4 months
Monotherapy followed by 4 weekly doses of rituximab [39]	R/R DLBCL	25	ORR 31% CR 21% PR 13%	mEFS 2.5 months mOS 8.1 months 5-year OS 53% (all patients) 81% (long-term responders)
Z-BEAM [40]	R/R DLBCL	43	ORR 98% CR 98%	2-year PFS 59% 2-year OS 91%
Z-BEAM [41]	Transformed lymphoma	63	ORR 100%	2-year PFS 68% 2-year OS 90%
After 3 cycles of R-CHOP and in association with ASCT [42]	DLBCL patients in PR or CRu after first line treatmen	37	ORR 100%	mPFS 5.1 years mDFS 4.3 years mOS 7.8 years

Abbreviations: DLBCL diffuse large B cell lymphoma; ORR overall response rate; CR complete response; PR partial response; mPFS median progression-free survival; mOS median overall survival; R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R/R relapsed/refractory; mEFS median event free survival; BEAM carmustine, etoposide, cytarabine, and melphalan; ASCT autologous stem cell transplantation; mDFS median disease free survival.